R. Stephenson

Repetitively dosed docetaxel and 153samarium‐EDTMP as an antitumor strategy for metastatic castration‐resistant prostate cancer

S. Larson, M. Morris, H. Scher, 2013, Cancer.

Phase I/II study of docetaxel and 153Sm for castrate metastatic prostate cancer (CMPC): Summary of dose-escalation cohorts and first report on the expansion cohort.

S. Larson, M. Morris, H. Scher, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.

L. Schwartz, M. Morris, H. Scher, 2009, European urology.

Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.

S. Larson, M. Morris, H. Scher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Virtual Tumor Board Increases Provider Attendance and Case Presentations

H. Pitt, D. August, A. Berger, 2022, JCO oncology practice.

Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.

S. Larson, L. Schwartz, M. Morris, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?

John L Pfail, T. Jang, S. Ghodoussipour, 2023, Current Urology Reports.